This program funds the acceleration of Parkinson's disease therapy development by supporting projects that generate meaningful evidence for critical milestones. It covers pre-clinical and clinical development of disease-modifying or symptomatic interventions and supports biomarker tool integration and analysis. Funding ranges from $1M to $5M over 2-3 years, targeting industry and academic-industry partnerships with a focus on commercialization. Early-stage discovery and non-therapeutic studies are excluded.
Open to industry and academic-industry partnerships aiming for commercialization. Some academic-led projects may qualify under eligibility exemptions.
